MREO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mereo BioPharma Group PLC (MREO) is not a good buy for a beginner investor with a long-term strategy at this time. The stock lacks strong positive catalysts, has bearish technical indicators, and faces challenges such as missed clinical trial endpoints and a recent downgrade by JPMorgan. Additionally, the financial performance is weak, with no revenue growth and a significant EPS decline. While the options data shows low put-call ratios, suggesting limited bearish sentiment, this is insufficient to justify a buy recommendation.
The MACD is slightly positive but contracting, and RSI is neutral at 29.181. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. Key support is at 0.307, and resistance is at 0.348. Overall, the technical indicators do not support a strong buy signal.
NULL identified. No recent news or significant positive developments.
Missed primary endpoints in Phase 3 clinical trials for setrusumab. JPMorgan downgraded the stock to Neutral, citing regulatory uncertainty. Weak financial performance with no revenue growth and a significant EPS decline.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income of -$7.35M, and an EPS decline of -83.33% YoY. Gross margin remained unchanged at 73.4%. Overall, financials indicate poor performance.
JPMorgan downgraded MREO to Neutral from Overweight, citing uncertainty in the regulatory process for its setrusumab program and missed clinical trial endpoints. No price target provided.
